The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Why aren't physicians prescribing more buprenorphine?
Open accessAbstract
Background & Objective Buprenorphine is an underutilized pharmacotherapy that can play a key role in combating the opioid epidemic. Individuals with opioid use disorder (OUD) often struggle to find physicians that prescribe buprenorphine. Many physicians do not have the waiver to prescribe buprenorphine, and a large proportion of physicians that are waivered do not prescribe to capacity. This study aimed to quantitatively understand why physicians do not utilize buprenorphine for the treatment of OUD more frequently. Methods Physicians (n=558) with and without the waiver to prescribe buprenorphine were surveyed about perceived drawbacks associated with prescribing buprenorphine. Furthermore, resources were identified that would encourage those without the waiver to obtain it, and those with the waiver to accept more new patients. The survey was distributed online to physicians in the spring/summer of 2016 via the American Society for Addiction Medicine and American Medical Association Listervs. Results and Conclusions A logistic regression analysis was used to identify reasons that respondents indicated no willingness to increase prescribing (2(4) = 73.18, p < .001); main reasons were lack of belief in agonist treatment (or 3.98, 95% CI, 1.43 to 11.1, p = .008), lack of time for additional patients (or 5.54, 95% CI, 3.5 to 8.7, p < .001), and belief that reimbursement rates are insufficient (or 2.50, 95% CI, 1.3 to 4.8, p = .006). Differences between non-waivered and waivered physicians concerning attitudes toward buprenorphine treatment as well as resources that would increase willingness to prescribe are also discussed. Identifying barriers to buprenorphine utilization is crucial in expanding treatment options for individuals with OUD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Selwyn, P. A., Hartel, D., Lewis, V. A., Schoenbaum, E. E., Vermund, S. H., Klein, R. S., Walker, A. T., & Friedland, G. H. (1989) · New England Journal of Medicine · doi:10.1056/nejm198903023200901 · Cited by 1,574
Vital signs: overdoses of prescription opioid pain relievers---United States, 1999--2008.
Paulozzi, L. J., Jones, C. M., Mack, K. A., & Rudd, R. A. (2011) · PubMed · Cited by 1,529
The Changing Face of Heroin Use in the United States: A Retrospective Analysis of the Past 50 Years
Cicero, T. J., Ellis, M. S., Surratt, H. L., & Kurtz, S. P. (2014) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2014.366 · Cited by 1,168
Relationship between Nonmedical Prescription-Opioid Use and Heroin Use
Compton, W. M., Jones, C. M., & Baldwin, G. T. (2016) · New England Journal of Medicine · doi:10.1056/nejmra1508490 · Cited by 1,044
Medication-Assisted Therapies — Tackling the Opioid-Overdose Epidemic
Volkow, N. D., Frieden, T. R., Hyde, P. S., & Cha, S. S. (2014) · New England Journal of Medicine · doi:10.1056/nejmp1402780 · Cited by 1,015
Jasinski, D. R. (1978) · Archives of General Psychiatry · doi:10.1001/archpsyc.1978.01770280111012 · Cited by 782
National and state treatment need and capacity for opioid agonist medication-assisted treatment
Jones, C. M., Campopiano, M., Baldwin, G., & McCance-Katz, E. (2015) · American Journal of Public Health · doi:10.2105/ajph.2015.302664 · Cited by 668
Vital signs: overdoses of prescription opioid pain relievers---United States, 1999--2008.
(2011) · PubMed · Cited by 640
Fudala, P. J., Bridge, T. P., Herbert, S., Williford, W. O., Chiang, C. N., Jones, K., Collins, J., Raisch, D., Casadonte, P., Goldsmith, R. J., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022164 · Cited by 577 · cited 1×
“Federal opiate treatment guidelines (SAMHSA, 2015a) also stipulate that patients have reasonable access to services such as counseling and that buprenorphine providers work to reduce the risk of medication diversion (Fudala et al., 2003).”
BackgroundTreatment of opioid-use disorders
Schuckit, M. A. (2016) · New England Journal of Medicine · doi:10.1056/nejmra1604339 · Cited by 540
Geographic and Specialty Distribution of US Physicians Trained to Treat Opioid Use Disorder
Rosenblatt, R. A., Andrilla, C. H. A., Catlin, M., & Larson, E. H. (2015) · The Annals of Family Medicine · doi:10.1370/afm.1735 · Cited by 380
Barriers to Primary Care Physicians Prescribing Buprenorphine
Hutchinson, E., Catlin, M., Andrilla, C. H. A., Baldwin, L.-M., & Rosenblatt, R. A. (2014) · The Annals of Family Medicine · doi:10.1370/afm.1595 · Cited by 289
Health, United States, 2013 : with special feature on prescription drugs
Holmes, J. S., & Arispe, I. E. (2014) · Cited by 245
Buprenorphine: how to use it right
JOHNSON, R. (2003) · Drug and Alcohol Dependence · doi:10.1016/s0376-8716(03)00060-7 · Cited by 241
Office-Based Management of Opioid Dependence with Buprenorphine: Clinical Practices and Barriers
Walley, A. Y., Alperen, J. K., Cheng, D. M., Botticelli, M., Castro-Donlan, C., Samet, J. H., & Alford, D. P. (2008) · Journal of General Internal Medicine · doi:10.1007/s11606-008-0686-x · Cited by 219
Drug-poisoning deaths involving heroin: United States, 2000-2013.
Hedegaard, H. B., Chen, L.-H., & Warner, M. (2015) · PubMed · Cited by 202
Analysis of barriers to adoption of buprenorphine maintenance therapy by family physicians
DeFlavio, J., Rolin, S. A., Nordstrom, B. R., & Kazal, L. A. (2015) · Rural and Remote Health · doi:10.22605/rrh3019 · Cited by 159
Illicit Use of Buprenorphine/Naloxone Among Injecting and Noninjecting Opioid Users
Bazazi, A. R., Yokell, M. A., Fu, J. J., Rich, J. D., & Zaller, N. D. (2010) · Journal of Addiction Medicine · doi:10.1097/adm.0b013e3182034e31 · Cited by 140
Buprenorphine diffusion: the attitudes of substance abuse treatment counselors
Knudsen, H. K., Ducharme, L. J., Roman, P. M., & Link, T. C. (2005) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2005.05.002 · Cited by 137
Kissin, W., McLeod, C. C., Sonnefeld, J., & Stanton, A. (2006) · Journal of Addictive Diseases · doi:10.1300/j069v25n04_09 · Cited by 109
PrEP in substance abuse treatment: a qualitative study of treatment provider perspectives
Spector, A. Y., Remien, R. H., & Tross, S. (2015) · Substance Abuse Treatment Prevention and Policy · doi:10.1186/1747-597x-10-1 · Cited by 107
Stein, B. D., Pacula, R. L., Gordon, A. J., Burns, R. M., LESLIE, D. L., Sorbero, M., Bauhoff, S., Mandell, T. W., & Dick, A. W. (2015) · Milbank Quarterly · doi:10.1111/1468-0009.12137 · Cited by 100
Cunningham, C. O., Kunins, H. V., Roose, R. J., Elam, R. T., & Sohler, N. (2007) · Journal of General Internal Medicine · doi:10.1007/s11606-007-0264-7 · Cited by 89
Knudsen, H. K. (2015) · Journal of Studies on Alcohol and Drugs · doi:10.15288/jsad.2015.76.644 · Cited by 78
The Untapped Potential of Office-Based Buprenorphine Treatment
Sigmon, S. C. (2015) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2014.2421 · Cited by 74
Parks, C. L., Reif, S., Haq, S., Wallack, S. S., Hoyt, A., & Ritter, G. A. (2008) · Psychiatric Services · doi:10.1176/ps.2008.59.8.909 · Cited by 69
Egan, J. E., Casadonte, P. P., Gartenmann, T., Martin, J., McCance‐Katz, E. F., Netherland, J. C., Renner, J. A., Weiss, L., Saxon, A. J., & Fiellin, D. A. (2010) · Journal of General Internal Medicine · doi:10.1007/s11606-010-1377-y · Cited by 68
Turner, B. J., Laine, C. M., Lin, Y., & Lynch, K. G. (2005) · Archives of Internal Medicine · doi:10.1001/archinte.165.15.1769 · Cited by 68
Buprenorphine prescribing practice trends and attitudes among New York providers
Kermack, A. S., Flannery, M., Tofighi, B., McNeely, J., & Lee, J. D. (2016) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2016.10.005 · Cited by 66
Cunningham, C. O., Sohler, N., McCoy, K., & Kunins, H. V. (2006) · PubMed · Cited by 60
Implementing buprenorphine in addiction treatment: payer and provider perspectives in Ohio
Molfenter, T. D., Sherbeck, C., Zehner, M. E., Quanbeck, A., McCarty, D. W., Kim, J.-S., & Starr, S. (2015) · Substance Abuse Treatment Prevention and Policy · doi:10.1186/s13011-015-0009-2 · Cited by 56
Khan, N. U. Z., Rasheed, S., Sharmin, T., Ahmed, T., Mahmood, S. S., Khatun, F., Hanifi, S., Hoque, S., Iqbal, M., & Bhuiya, A. (2015) · BMC Medical Informatics and Decision Making · doi:10.1186/s12911-015-0188-9 · Cited by 55
Nordstrom, B. R., Saunders, E. C., McLeman, B. M., Meier, A., Xie, H., Lambert-Harris, C. A., Tanzman, B., Brooklyn, J. R., King, G., Kloster, N., et al. (2016) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000000200 · Cited by 47
WINSTOCK, A. R., & Lea, T. (2009) · Substance Use & Misuse · doi:10.3109/10826080903080664 · Cited by 46
The Effect of Childhood Supervisory Neglect on Emerging Adults’ Drinking
Snyder, S. M., & Merritt, D. H. (2016) · Substance Use & Misuse · doi:10.3109/10826084.2015.1073321 · Cited by 39
Methadone- and Heroin-Related Deaths in Florida
Graham, N. A., Merlo, L. J., Goldberger, B. A., & Gold, M. S. (2008) · The American Journal of Drug and Alcohol Abuse · doi:10.1080/00952990802010892 · Cited by 36
Erin, K., Paul, D., Amir, A., & Clare, L. (2015) · Studies in Health Technology and Informatics · doi:10.3233/978-1-61499-505-0-38 · Cited by 35
Saurman, E., Lyle, D. M., Perkins, D. A., & Roberts, R. J. (2013) · Australian Health Review · doi:10.1071/ah13050 · Cited by 34
Knudsen, H. K., Lofwall, M. R., Havens, J. R., & WALSH, S. L. (2015) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2015.09.032 · Cited by 31
Determinants of buprenorphine treatment for opioid dependence
Murphy, S. M., Fishman, P. A., McPherson, S., Dyck, D. G., & Roll, J. M. (2013) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2013.09.003 · Cited by 24
Should the United States Government Repeal Restrictions on Buprenorphine/Naloxone Treatment?
Blum, K., Gold, M. S., Clark, H. W., et al. (2016) · Substance Use & Misuse · doi:10.1080/10826084.2016.1200097 · Cited by 16
Campanella, N., Morosini, P., Sampaolo, G., Catozzo, V., Caso, A., Ferretti, M., Giovagnoli, M., Torniai, M., & Antico, E. (2015) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2015.08.010 · Cited by 9
Cited by
Stigma as a fundamental hindrance to the United States opioid overdose crisis response
Tsai, A. C., Kiang, M. V., Barnett, M. L., Beletsky, L., Keyes, K. M., McGinty, E. E., Smith, L. R., Strathdee, S. A., Wakeman, S. E., & Venkataramani, A. S. (2019) · PLOS Medicine · doi:10.1371/journal.pmed.1002969 · Cited by 437
Medications for management of opioid use disorder
Koehl, J. L., Zimmerman, D. E., & Bridgeman, P. J. (2019) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxz105 · Cited by 90
Sokol, R., Albanese, M., Chew, A., Early, J., Grossman, E., Roll, D., Sawin, G., Wu, D. J., & Schuman-Olivier, Z. (2019) · Addiction Science & Clinical Practice · doi:10.1186/s13722-019-0176-y · Cited by 14
Richards, M. R., Leech, A. A., Stein, B. D., Buntin, M. B., & Patrick, S. W. (2023) · Medical Care · doi:10.1097/mlr.0000000000001851 · Cited by 1
Metadata
- Authors
- Huhn, A. S., & Dunn, K. E.
- Venue
- Journal of Substance Abuse Treatment
- Publisher
- Elsevier BV
- Published
- 2017-07
- Volume
- 78
- Pages
- 1-7
- ISSN
- 0740-5472 (ISSN-L)
- OpenAlex
- W2606264631
- Cited by
- 291
- References
- 43
- FWCI
- 25.45
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.